AM Pharma

About:

AM-Pharma is a biopharmaceutical company focused on the development of therapeutics to treat inflammatory and infectious diseases.

Website: http://www.am-pharma.com/

Top Investors: European Investment Bank, Andera Partners, Pfizer, AbbVie, EQT Life Sciences

Description:

AM-Pharma B.V., a biopharmaceutical company, engages in the development and commercialization of therapeutics for human use in the Netherlands. It focuses in the pre-clinical and clinical development of novel therapeutics to treat inflammatory and infectious diseases. The company develops products based on endogenous proteins and protein derived peptides, as well as molecules that naturally occur in the human body. Its products include alkaline phosphatase for treatment of acute kidney injury and ulcerative colitis; and immune response amplifying peptide hLF1-11 for the treatment of drug resistant hospital acquired infections. The company was founded in 2000 and is headquartered in Bunnik, the Netherlands.

Total Funding Amount:

208M EUR

Headquarters Location:

Bunnik, Utrecht, The Netherlands

Founded Date:

2000-01-01

Founders:

Martin Hessing

Number of Employees:

11-50

Last Funding Date:

2021-07-01

IPO Status:

Private

Industries:

© 2025 bioDAO.ai